¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Refractory anaemia with excess of blasts with transformation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blastic transformation
    ¸ð¼¼Æ÷Àüȯ
  • malignant transformation
    ¾Ç¼ºÀüȯ
  • radioactive transformation
    ¹æ»ç´ÉÀüȯ
  • absolute refractory period
    Àý´ëºÒÀÀ±â
  • functional refractory period
    ±â´ÉÀûºÒÀÀ±â
  • refractory
    1. ºÒÀÀ-, ¹«¹ÝÀÀ¼º- 2. Ä¡·áÀúÇ×¼º-, ³­Ä¡¼º-
  • refractory investment
    ³»È­¸Å¸ôÁ¦
  • refractory normoblastic anemia
    ³­Ä¡¼ºÁ¤»óÀûÇ÷¸ð±¸ºóÇ÷
  • refractory period
    ºÒÀÀ±â
  • refractory rickets
    ºñŸ¹ÎDºÒÀÀ±¸·çº´, ºÒÀÀ¼º±¸·çº´
  • refractory state
    ºÒÀÀ»óÅÂ
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antigen excess
    Ç׿ø°úÀ×
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excess
    °ú´Ù, °úÀ×
  • antigen excess
    Ç׿ø°úÀ×
  • refractory period
    ºÒÀÀ±â
  • refractory state
    ¹«¹ÝÀÀ»óÅÂ
  • transformation
    Àüȯ, ÇüÁúÀüȯ, º¯È¯
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • transformation zone
    º¯ÇüÃþ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • abortive transformation
    ºÒ¹ßÇüÁúÀüȯ
  • antigenic transformation
    Ç׿øº¯È¯
  • artificial transformation
    Àΰøº¯È¯
  • isometric transformation
    µîÀ庯ȯ
  • lymphoblastic transformation test
    ¸²ÇÁ¸ð¼¼Æ÷Àüȯ°Ë»ç
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • radioactive transformation
    ¹æ»ç´ÉÀüȯ
  • transformation
    Àüȯ, ÇüÁúÀüȯ
  • absolute refractory period
    Àý´ëºÒÀÀ±â
  • normoblastic refractory anemia
    Á¤»óÀûÇ÷¸ð±¸Áö¿¬¹ÝÀÀºóÇ÷
  • functional refractory period
    ±â´ÉÀûºÒÀÀ±â
  • refractory investment
    ³»È­¸Å¸ôÁ¦
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • refractory period
    ºÒÀÀ±â
  • relative refractory period
    »ó´ëºÒÀÀ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alimentary anemia<³ª> anaemia alimentria
    ½Ä»ç¼º ºóÇ÷(?Ë×Ì´).
  • 2D FT (2D Fourier transformation)
    2Â÷¿ø Fourier º¯È¯ (2Â÷¿ø Ç»¸®¾î º¯È¯)
  • abortive transformation
    ºÒ¹ßÇüÁúÀüȯ, ºÎÀüÇüÁúÀüȯ
  • antigenic transformation
    Ç׿øº¯È¯(ù÷ê«Ü¨üµ).
  • artificial transformation
    Àΰøº¯È¯(¡­Ü¨üµ).
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • absolute refractory period
    Àý´ëºÒÀÀ±â(¡­ÝÕëëÑ¢)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • refractory anemia with excess blasts
    ¸ð¼¼Æ÷°ú´Ù¼º ºÒÀÀ¼ººóÇ÷
  • refractory anemia with excess blast =RAEB
    ¸ð¼¼Æ÷°ú´ÙºÒÀÀ¼ººóÇ÷
  • alimentary anemia<³ª> anaemia alimentria
    ½Ä»ç¼º ºóÇ÷(?Ë×Ì´).
  • abortive transformation
    ºÒ¹ßÇüÁúÀüȯ, ºÎÀüÇüÁúÀüȯ
  • antigenic transformation
    Ç׿øº¯È¯(ù÷ê«Ü¨üµ).
  • artificial transformation
    Àΰøº¯È¯(¡­Ü¨üµ).
  • cell transformation
    ¼¼Æ÷ÇüÁúÀüȯ, ¼¼Æ÷º¯Çü
  • conformal transformation
    °øÇüº¯È¯(Ë­Ì´ËÒÌ·).
  • conformal transformation
    °øÇüº¯È¯(Íìû¡Ü¨üµ).
  • fast Fourier transformation
    °í¼Ó (ÍÔáÜ) Ǫ¸®¿¡ º¯È¯ (ܨüµ)
  • isometric transformation
    µîÀ庯ȯ(¡­Ü¨üµ).
  • leukemic cell transformation
    ¹éÇ÷º´ ¼¼Æ÷ Àüȯ
  • lymphoblastic transformation test
    ¸²ÇÁ¾Æ¼¼Æ÷Àüȯ½ÃÇè
  • lymphocyte transformation
    ¸²ÇÁ±¸Àüȯ(¡­Ï¹ ï®üµ).
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • refractory prriod
    ºÒÀÀ±â(Ñ¢)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • atomic percent excess
    °ú´Ù ¿øÀÚ¹éºÐÀ²(ΦÒýê«í­ÛÝÝÂëÒ)
  • primary alkali excess
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®°úÀ×(Φí¥)
  • primary carbon dioxide excess
    ¿ø¹ß¼º ÀÌ»êȭź¼Ò(ê´Û¡àõ ì£ß«ûù÷©áÈ) °úÀ×(Φí¥)
  • CaCl2 transformation
    CaCl2 º¯Çü¼ú(ܨû¡âú)
  • calcium chloride transformation
    ¿°È­Ä®½· º¯Çü¼ú(ܨû¡âú)
  • closure transformation
    ºÀÇÕ º¯Çü(Üñùêܨû¡)
  • double transformation
    ÀÌÁß º¯Çü(ì£ñìܨû¡) (ÔÒ) cotransformation
  • joint transformation
    °øµ¿º¯Çü(ÍìÔÒܨû¡)
  • Kronig-Kramer transformation
    Å©·Î´Ï±×-Å©¶ó¸Ó º¯Çü(ܨû¡)
  • linear transformation
    ¼±ÇüÀüȯ(àÊû¡ï®üµ)
  • linked transformation
    ¿¬°üº¯Çü(֤μܨû¡)
  • Lobry De Bruyn-Alberta van Eckenstein transformation
    ·Îºê¸® µå ºê¸¥-¾Ë¹öŸ ¹Ý ¿¡Ä˽ºÅ¸ÀÎ º¯Çü(ܨû¡)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excess
    °úÀ×, À׿©
  • 2D FT [=2D Fourier transformation]
    2Â÷¿øFourierº¯È¯
  • magnetic transformation
    ÀÚ±âÀüȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RAEB-T Refractory Anemia with Excess Blasts in Transformation
RAEBiT, RAEB-T refractory anemia with excess blasts in transformation
RAEB Refractory Anemia with Excess of Blasts
RAEB refractory anemia with excess blasts
REAB refractory anemia with excess of blasts
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RAEB-t refractory anaemia with excess of blasts 'in transformation
RAEB-T Refractory anemia with excess blasts in transformation
RAEB Refractory anaemia with excess of blasts
RAEB refractory anaemia with an excess of blasts
RAEB refractory anaemia with excess blasts
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • D46.3
    Refractory anaemia with excess of blasts with transformation
    ÇüÁúÀüȯÀ» µ¿¹ÝÇÑ ¸ð±¸°úÀ×ÀÇ ºÒÀÀ¼º ºóÇ÷
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • refractory cast
    ³»È­¼º ¸ðÇü
    ºÐÇØµÇÁö ¾Ê°í °í¿­À» °ßµô ¼ö ÀÖ´Â Àç·á·Î ¸¸µé¾îÁø ¸ðÇüÀ¸·Î¼­, ±¹¼Ò ÀÇÄ¡ ÁÖÁ¶¼ú¿¡ »ç¿ëµÉ ¶§ ÆØÃ¢ÇÏ¿© ±Ý¼ÓÀÇ ¼öÃàÀ» º¸»óÇÑ´Ù.
  • refractory investment
    ³»È­ ¸Å¸ôÁ¦, ³»È­¼º ¸Å¸ôÀç
    ³³ÂøÀ̳ª ÁÖÁ¶¿¡ »ç¿ëµÇ´Â °í¿Â¿¡ °ßµô¼ö ÀÖ´Â ¸Å¸ôÀç.
  • refractory mold
    ³»È­¼º ¸ôµå
  • sideroblastic refractory anemia
    ö Àû¸ð±¸¼º ºÒÀÀ¼º ºóÇ÷
  • conformal transformation
    °øÇü º¯È¯
  • order-disorder transformation
    ±ÔÄ¢-ºÒ±ÔÄ¢ º¯ÅÂ
    ¿ë¸Å ¿øÀÚ¿Í ¿ëÁú ¿øÀÚ°¡ ÀÓÀÇ·Î ¹è¿­Çϰí ÀÖ´Â ºÒ±ÔÄ¢ °ÝÀÚ¿¡¼­ ±ÔÄ¢ ¹Ù¸¥ ¹è¿­ÀÇ ±ÔÄ¢ °ÝÀÚ·Î º¯ÇÏ´Â º¯ÅÂ.
  • physical transformation
    ¹°¸®Àû º¯Çü
  • sex transformation
    ¼º Àüȯ
    ¿¬¼Ò±â¿¡ ¼º¼±À» Á¦°ÅÇÏ¸é ³²³à Áß°£ °³Ã¼³ª À̼ºÀÇ Æ¯Â¡ÀÌ ¹ßÇöµÈ´Ù.
  • transformation gauge
    º¯È¯ °ÔÀÌÁö
  • antibody excess zone
    Ç×ü °úÀ׿ª
  • antigen excess
    Ç׿ø °úÀ×
    ħ°­ ¹ÝÀÀ µî ÃÖÀûºñ¿¡¼­ ¹ÝÀÀÀÌ Àß °üÂûµÇ´Â °æ¿ì Ç׿øÀÇ ¾çÀÌ Áö³ªÄ¡°Ô ¸¹À¸¸é ¹Ý´ë·Î ¹ÝÀÀÀÌ ¾àÇØÁö°í °üÂûÀÌ °¡´ÉÇÑ ¹ÝÀÀÀÌ »ý±æ ¶§±îÁöÀÇ ½Ã°£ÀÌ ±æ¾îÁø´Ù. ÀÌ¿Í °°ÀÌ Ç׿øÀÌ °úÀ×µÇ¾î ¹ÝÀÀÀÌ °üÂûµÇÁö ¾Ê°Ô µÇ´Â °æ¿ì Ç׿ø °úÀ׿¡ ÀÇÇÑ ¹ÝÀÀÀÇ ¾ïÁ¦Çϰí ÇÑ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â Ç׿ø °úÀ×ÀÎ °æ¿ì¿¡´Â °¡¿ë¼ºÀÌ µÈ´Ù.
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • excess
    °úÀ×, À׿©
  • excess chlorine
    °úÀ× ¿°¼Ò
  • excess factor
    °úÀ× ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
anaemia, refractory, with excess of blasts Chronic refractory anaemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
(12 Dec 1998)
refractory anaemia with excess blasts <haematology> A form of myelodysplasia characterised by the build up of immature white blood cells (blasts) in the bone marrow.
If the immature cells are particularly numerous it may indicate a chance of transformation to acute leukaemia and the condition is called refractory anaemia with excess blasts in transformation (RAEBt).
Acronym: RAEB
(13 Nov 1997)
anaemia, refractory Anaemia (a shortage of red blood cells) unresponsive to treatment.
(12 Dec 1998)
refractory anaemia <haematology> A form of myelodysplasia which primarily affects the red cell production by the bone marrow.
In some cases the developing red cells show an internal ring of iron granules. These cells are called sideroblasts. Refractory anaemia and refractory anaemia with sideroblasts are the most common forms of myelodysplasia.
Origin: Gr. Haima = blood
(13 Nov 1997)
primary refractory anaemia Any of a group of anaemic conditions in which there is persistent, frequently advanced anaemia that is not successfully treated by any means except blood transfusions, and that is not associated with another primary disease.
(05 Mar 2000)
secondary refractory anaemia Any persistent anaemia that is successfully treated only by blood transfusions, and that is associated with another condition.
(05 Mar 2000)
blasts Immature blood cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
base excess A measure of metabolic alkalosis, usually predicted from the Siggaard-Andersen nomogram; the amount of strong acid that would have to be added per unit volume of whole blood to titrate it to pH 7.4 while at 37°C and at a carbon dioxide pressure of 40 mm Hg.
(05 Mar 2000)
calcium excess Overly high intake of calcium (hypercalcaemia) may cause muscle weakness and constipation, affect the conduction of electrical impulses in the heart (heart block) lead to calcium stones in the urinary tract, impair kidney function (through nephrocalcinosis), and interfere with the absorption of iron predisposing to iron deficiency. According to the National Academy of Sciences, adequate intake of calcium is 1 gram daily for both men and women. The upper limit for calcium intake is 2.5 grams daily.
(12 Dec 1998)
magnesium excess Persons with impaired kidney function should be especially careful about their magnesium intake because they can accumulate magnesium, a dangerous situation. According to the national academy of sciences, the recommended dietary allowances of magnesium are 420 milligrams per day for men and 320 milligrams per day for women. The upper limit of magnesium as supplements is 350 milligrams daily, in addition to the magnesium from food and water.
(12 Dec 1998)
convergence excess That condition in which an oesophoria or esotropia is greater for near vision than for far vision.
(05 Mar 2000)
selenium excess Too much of the mineral selenium may cause reversible changes in the hair (balding) and nails, garlic odour to the breath, intestinal distress, weakness and slower mentation (slowed mental functionning). According to the national academy of sciences, the recommended dietary allowances of selenium are 70 milligrams per day for men and 55 milligrams per day for women.
(12 Dec 1998)
negative base excess A measure of metabolic acidosis, usually predicted from the Siggaard-Andersen nomogram; the amount of strong alkali that would have to be added per unit volume of whole blood to titrate it to pH 7.4 while at 37°C and at a carbon dioxide pressure of 40 mm Hg.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • refractory
    ´Ù·ç±â Èûµç; ³­Ä¡ÀÇ
  • anaemia
    =anemia;anemic
  • aplastic anaemia
    Àç»ýºÒ·®¼ººóÇ÷
  • refractory
    (»ç¶÷.µ¿¹° µîÀÌ)°¨´çÇÒ ¼ö ¾ø´Â;´Ù·ç±â Èûµå´Â;¼øÁ¾ÇÏÁö ¾Ê´Â;³­Ä¡ÀÇ;¿Ï°íÇÑ;(º´ µî¿¡)ÀúÇ× ÇÒ ¼ö ÀÖ´Â;º´µ¶¿¡ °¨¿°µÇÁö ¾Ê´Â;(±Ý¼Ó µîÀÌ)¿ëÇØ(ó¸®)Çϱ⠾î·Á¿î;(º®µ¹ µîÀÌ)³»È­¼ºÀÇ;³»È­ ¹°Áú;³»È­ º®µ¹;-riness
  • transformation
    º¯Çü
  • microbial transformation
    ¹Ì»ý¹° º¯È¯
  • transformation
    º¯Çü;º¯¸ð;º¯Áú
  • transformation scene
    (¸·À» ³»¸®Áö ¾Ê´Â) »¡¸® º¯ÇÏ´Â Àå¸é
  • transformation theory
    º¯Çü¼³
  • excess
    °ú´Ù(ÀÇ); ÆøÀ½(½Ä)
  • excess
    °úµµ;°ú´Ù;°úÀ×;Ãʰú;Ãʰú·®;ºÎÀýÁ¦;Áö³ªÄ§;³­Æø;ÆøÀ½Æø½Ä(excess of imports over exports ¼öÀÔ Ãʰú) a
  • excess baggage
    Á¦ÇÑ Ãʰú ¼öÇϹ°
  • excess charge
    ÁÖÂ÷ ½Ã°£ Ãʰú ¿ä±Ý
  • excess fare
    öµµÀÇ °Å¸® Ãʰú ¿ä±Ý;Ãʰú ¿ä±Ý
  • excess luggage
    =EXCESS BAGGAGE
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á